Are we starting to induce skin cancer in order to avoid topical steroids? [7]

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 3, 2005, Pages 387-389

  Niwa, Y ^a   Nasr, I ^b  

^a Niwa Institute for Immunology   (Japan)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; STEROID; SUNSCREEN; TACROLIMUS;

ATOPIC DERMATITIS; CANCER RISK; CHILD; CLOTHING; DRUG SAFETY; HELPER CELL; HUMAN; LETTER; MOUSE STRAIN; NONHUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; SKIN CANCER; SKIN CARCINOGENESIS; SKIN PROTECTION; SUN EXPOSURE; SUPPRESSOR CELL; ULTRAVIOLET RADIATION;

ACNE VULGARIS; ANIMALS; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED HRS; SKIN NEOPLASMS; STEROIDS; TACROLIMUS;

EID: 18844382616     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.01123.x     Document Type: Letter

References (5)

1. Fujisawa Limited. Protopic 0.1% ointment: information leaflet. Emc.vhn.net URL: http://emc.vhn.net/eMC/assets/c/html/DisplayDoc.asp?DocumentId=8816
2. Niwa Y. Topical tacrolimus potentiates carcinogenesis in mouse skin and reduces the lymph node CD4/CD8 ratio. Jpn J Allergol 2003; 52: 333 (Abstr.) (in Japanese).
3. Niwa Y, Terashima T, Sumi H. Topical tacrolimus accelerates tumor formation and carcinogenesis in mouse skin. J Invest Dermatol 2002; 119: 749 (Abstr.).
4. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149: 960-967.
5. Homey B, Assmann T, Vohr HW et al. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol 1998; 160: 5331-5340.